1324 related articles for article (PubMed ID: 24858371)
1. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
2. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
[TBL] [Abstract][Full Text] [Related]
3. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD
Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808
[TBL] [Abstract][Full Text] [Related]
4. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
[TBL] [Abstract][Full Text] [Related]
5. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
[TBL] [Abstract][Full Text] [Related]
6. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
7. Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
Luo J; Nguyen K; Chen M; Tran T; Hao J; Tian B; Rulifson IC; Zhang Y; Tian L; Zhang Y; Lopez E; Lin DC; Wang Y; Ma Z; Houze J; Guo Z
Metabolism; 2013 Jan; 62(1):90-9. PubMed ID: 22982177
[TBL] [Abstract][Full Text] [Related]
8. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.
Yashiro H; Tsujihata Y; Takeuchi K; Hazama M; Johnson PR; Rorsman P
J Pharmacol Exp Ther; 2012 Feb; 340(2):483-9. PubMed ID: 22106100
[TBL] [Abstract][Full Text] [Related]
9. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
Zheng YC
Yao Xue Xue Bao; 2015 Dec; 50(12):1668-72. PubMed ID: 27169293
[TBL] [Abstract][Full Text] [Related]
10. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
11. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.
Tanaka H; Yoshida S; Minoura H; Negoro K; Shimaya A; Shimokawa T; Shibasaki M
Life Sci; 2014 Jan; 94(2):115-21. PubMed ID: 24269216
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
[TBL] [Abstract][Full Text] [Related]
14. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
[TBL] [Abstract][Full Text] [Related]
16. Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Kimura T; Toda N
Bioorg Med Chem; 2015 Sep; 23(17):5546-65. PubMed ID: 26234904
[TBL] [Abstract][Full Text] [Related]
17. The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1.
Sundström L; Myhre S; Sundqvist M; Ahnmark A; McCoull W; Raubo P; Groombridge SD; Polla M; Nyström AC; Kristensson L; Någård M; Winzell MS
PLoS One; 2017; 12(12):e0189060. PubMed ID: 29206860
[TBL] [Abstract][Full Text] [Related]
18. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
19. Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia.
Ionut V; Castro AV; Woolcott OO; Stefanovski D; Iyer MS; Broussard JL; Burch M; Elazary R; Kolka CM; Mkrtchyan H; Bediako IA; Bergman RN
Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E644-52. PubMed ID: 25117408
[TBL] [Abstract][Full Text] [Related]
20. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]